Sensitization to the cytotoxicity of adriamycin by verapamil and heat in multidrug-resistant Chinese hamster ovary cells

Radiation Research

Volumn 151, Issue 6, 1999, Pages 694-702

  Averill, Diana A ^a   Su, Chen ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CARBON 14; COLCHICINE; DOXORUBICIN; VERAPAMIL;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CHO CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; HEAT; HYPERTHERMIA; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TARGET ORGAN;

ANIMALS; CHO CELLS; CRICETINAE; DNA REPAIR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HEAT; VERAPAMIL;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0033054172     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.2307/3580208     Document Type: Article

References (64)

1. G. Bradley, P. F. Juranka and V. Ling, Mechanism of multidrug resistance. Biochim. Biophys. Acta 948, 87-128 (1988).
2. M. M. Cornwell, A. R. Safa, R. L. Felsted, M. M. Gottesman and I. Pastan, Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150 to 170 kDa protein detected by photoaffinity labeling. Proc. Natl. Acad. Sci. USA 83, 3847-3850 (1986).
3. M. M. Cornwell, T. Tsuruo, M. M. Gottesman and I. Pastan, ATP-binding properties of P-glycoprotein from multidrug-resistant KB cells. FASEB J. 1, 51-54 (1987).
4. J. R. Riordan and V. Ling, Genetic and biochemical characterization of multidrug resistance. Pharmacol. Ther. 28, 51-75 (1985).
5. J. R. Riordan, K. K. Deuchars, N. Kartner, N. Alon, J. Trent and V. Ling, Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316, 817-819 (1985).
6. E. Georges, F. J. Sharom and V. Ling, Multidrug resistance and chemosensitization: Therapeutic implications for cancer chemotherapy. Adv. Pharmacol. 21, 185-221 (1990).
7. J. R. Warr, M. Anderson and J. Fergusson, Properties of verapamil-hypersensitive multidrug-resistant Chinese hamster ovary cells. Cancer Res. 48, 4477-4483 (1988).
8. M. C. Willingham, M. M. Cornwell, C. O. Cardarelli, M. M. Gottesman and I. Pastan, Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: Effect of verapamil and other drugs. Cancer Res. 46, 5941-5946 (1986).
9. T. Skovsgaard, K. Dano and N. L. Nissen, Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo: A new treatment principle. Cancer Treat. Rev. 11 (Suppl. A), 63-72 (1984).
10. W. T. Beck, Cellular pharmacology of vinca alkaloid resistance and its circumvention. Adv. Enzyme Regul. 22, 207-227 (1984).
11. W. T. Beck, M. C. Cirtain, A. T. Look and R. A. Ashmun, Reversal of vinca alkaloid resistance but not multiple drug resistance in human leukemia cells by verapamil. Cancer Res. 46, 778-784 (1986).
12. W. S. Dalton, T. M. Grogan. B. G. M. Durie, P. S. Meltzer, R. J. Scheper, C. W. Taylor, T. W. Miller and S. E. Salmon, Drug resistance in B-cell neoplasms: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 7, 415-424 (1989).
13. F. Formelli, L. Cleris and R. Carsana, Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. Cancer Chemother. Pharmacol. 21, 921-930 (1988).
14. A. Gruber, C. Peterson and P. Reizenstein, D-Verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemia cells in vitro. Int. J. Cancer 41, 224-226 (1988).
15. A. A. Hindenburg, M. A. Baker, E. Gleyer, V. J. Stewart, N. Case and R. N. Taub, Effect of verapamil and other agents on the distribution of anthracyclines and on the reversal of drug resistance. Cancer Res. 47, 1421-1425 (1987).
16. R. F. Ozols, R. E. Cunnion, R. W. Klecker, T. C. Hamilton, Y. Ostchega, J. E. Parrillo and R. C. Young, Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5, 641-647 (1987).
17. L. M. Slater, P. Sweet, M. Murray, M. W. Wetzel, R. M. Wisdom and E. M. Duval, Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J. Clin. Invest. 70, 1131-1134 (1982).
18. T. Tsuruo, H. Lida, S. Tsukagoshi and Y. Sakurai, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41, 1967-1972 (1981).
19. M. M. Gottesman and I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385-427 (1993).
20. A. Skladanowski and J. Konopa, Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem. Pharmacol. 46, 375-382 (1993).
21. P. J. Vichi and T. R. Tritton, Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A. Cancer Res. 53, 5237-5243 (1993).
22. P. J. Vichi and T. R. Tritton, Adriamycin: Protection from cell death by removal of extracellular drug. Cancer Res. 52, 4135-4138 (1992).
23. B. K. Sinha, A. G. Katki, G. Batist, K. H. Cowan and C. E. Myers, Adriamycin stimulated hydroxyl radical formation in human breast tumor cells. Biochem. Pharmacol. 36, 793-796 (1987).
24. H. M. Coley, P. R. Twentyman and P. Workman, Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem. Pharmacol. 38, 4467-4475 (1989).
25. W. S. Dalton, B. G. Durie, D. S. Albert, J. H. Gerlach and A. E. Cress, Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 46, 5125-5130 (1986).
26. A. Krishan, A. Sauerteig and L. L. Wellham, Flow cytometric studies on modulation of cellular Adriamycin retention by phenothiazines. Cancer Res. 45, 1768-1773 (1985).
27. H. J. Broxterman, H. M. Pinedo, C. M. Kuiper, L. C. M. Kaptein, G. J. Schuurhuis and J. Lankelma, Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J. 2, 2278-2282 (1988).
28. J. A. Endicott and V. Ling, The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58, 137-171 (1989).
29. M. Horio, M. M. Gottesman and I. Pastan, ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc. Natl. Acad. Sci. USA 85, 3580-3584 (1988).
30. G. M. Hahn, Potential for therapy of drugs and hyperthermia. Cancer Res. 39, 2264-2268 (1979).
31. D. A. Bates and W. J. Mackillop, The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro. Br. J. Cancer 62, 183-188 (1990).
32. D. A. Bates and W. J. Mackillop, The effect of hyperthermia on the uptake and cytotoxicity of melphalan in Chinese hamster ovary cells. Int. J. Radiat. Oncol. Biol. Phys. 16, 187-191 (1989).
33. O. Dahl, Mechanisms of thermal enhancement of chemotherapeutic cytotoxicity. In Hyperthermia and Oncology (M. Urano and E. B. Douple, Eds.), Vol. 4, pp. 9-28. VSP, Utrecht, 1994.
34. G. P. Raaphorst, S. Doja, L. Davis, D. Stewart and C. E. Ng, A comparison of hyperthermia on cisplatin sensitization in human glioma and ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment. Cancer Chemother. Pharmacol. 37, 574-580 (1996).
35. D. A. Bates, L. L. Henritzy, A. Loutfi and W. J. Mackillop, The effect of hyperthermia on the cytotoxicity of melphalan in Chinese hamster ovary cells. Cancer Lett. 34, 145-155 (1987).
36. D. A. Bates and W. J. Mackillop, Hyperthermia, adriamycin transport, and cytotoxicity in drug-sensitive and -resistant Chinese hamster ovary cells. Cancer Res. 46, 5477-5481 (1986).
37. L. R. Towle, Hyperthermia and drug resistance. In Hyperthermia and Oncology (M. Urano and E. B. Douple, Eds.), Vol. 4, pp. 91-113. VSP, Utrecht, 1994.
38. V. Ling and L. H. Thompson, Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell Physiol. 83, 103-116 (1974).
39. G. Poch, Combined Effects of Drugs and Toxic Agents. Springer-Verlag, Wien, 1993.
40. K. E. Wallner and G. C. Li, Adriamycin resistance, heat resistance and radiation response in Chinese hamster fibroblasts. Int. J. Radiat. Oncol. Biol. Phys. 12, 829-833 (1986).
41. T. S. Herman, A. E. Cress, C. Sweets and E. W. Gerner, Reversal of resistance to methotrexate by hyperthermia in Chinese hamster ovary cells. Cancer Res. 41, 3840-4843 (1981).
42. K. E. Wallner, M. Banda and G. C. Li, Hyperthermic enhancement of cell killing by mitomycin C in mitomycin C-resistant Chinese hamster ovary cells. Cancer Res. 47, 1308-1312 (1987).
43. K. E. Wallner, M. W. De Gregorio and G. C. Li, Hyperthermia potentiation of diamminedichloroplatinum (II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res. 46, 6242-6245 (1986).
44. T. S. Herman, B. A. Teicher, K. N. Cathcart, M. E. Kaufman, J. B. Lee and M. H. Lee, Effect of hyperthermia on cis-diamminedichloroplatinum (II) and Pt(Rh-123)2 in a human squamous carcinoma cell line and a cis-diamminedichloroplatinum (II)-resistant subline. Cancer Res. 48, 5101-5105 (1988).
45. G. M. Hahn, Introduction. In Hyperthermia and Oncology (M. Urano and E. B. Douple, Eds.), Vol. 4, pp. 1-7. VSP, Utrecht, 1994.
46. J. L. Roti Roti and A. Laszlo, The effect of hyperthermia on cellular macromolecules. In Hyperthermia and Oncology (M. Urano and E. B. Douple, Eds.), Vol. 1, pp. 13-56. VSP, Utrecht, 1988.
47. J. R. Lepock and J. Kruuv, Mechanism of thermal cytotoxicity. In Hyperthermia Oncology 1992 (E. W. Gerner and T. C. Cetas, Eds.), Vol. 2, pp. 9-16. Arizona Board of Regents, 1993.
48. J. H. Doroshow, Anthracyclines and anthracenediones. In Cancer Chemotherapy and Biotherapy: Principles and Practice (B. A. Chabner and D. L. Longo, Eds.), 2nd ed, pp. 409-434. Lippincott-Raven, Philadelphia, 1996.
49. M. Dalmark and H. H. Strom, A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red cells. J. Gen. Physiol. 78, 349-364 (1981).
50. D. A. Bates and W. J. Mackillop, The relationship between membrane permeability to adriamycin and adriamycin cytotoxicity in CHO cells at elevated temperatures. Cancer Lett. 38, 129-135 (1987).
51. E. M. Elliott and V. Ling, Selection and characterization of Chinese hamster ovary cell mutants resistant to melphalan (L-phenylalanine mustard). Cancer Res. 41, 393-400 (1981).
52. W. T. Beck and M. K. Danks, Characteristics of multidrug resistance in human tumor cells. In Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells (I. B. Roninson, Ed.), pp. 3-55. Plenum Press, New York, 1991.
53. A. R. Safa, Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest. 11, 46-56 (1993).
54. R. Busche, B. Tummler, J. R. Riordan and D. F. Cano-Gauci, Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance. Mol. Pharmacol 35, 414-421 (1989).
55. A. R. Safa, Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc. Natl. Acad. Sci. USA 85, 7187-7191 (1988).
56. Y. Shoji, M. H. Fisher, A. Periasamy, B. Herman and R. L. Juliano, Verapamil and cyclosporin A modulate doxorubucin toxicity by distinct mechanisms. Cancer Lett. 57, 209-218 (1991).
57. I. Cleary, G. Doherty, E. Moran and M. Clynes, The multidrug-resistant human tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem. Pharmacol. 53, 1493-1502 (1997).
58. B. S. Glisson, Multidrug-resistance mediated through alterations in topoisomerase II. Cancer Bull. 41, 37-40 (1989).
59. L. Liu, DNA topoisomerase poison as antitumor drugs. Annu. Rev. Biochem. 58, 351-375 (1989).
60. C. P. Schrôder, A. K. Godwin, P. J. O'Dwyer, K. D. Tew, T. C. Hamilton and R. F. Ozols, Glutathione and drug resistance. Cancer Invest. 14, 158-168 (1996).
61. S. Tsuchida and K. Sato, Glutathione transferases and cancer. Crit. Rev. Biochem. Mol. Biol. 27, 337-384 (1992).
62. J. A. Plumb, R. Milroy and S. B. Kaye, The activity of verapamil as a resistance modifier in vitro in drug resistant human tumor cell lines is not stereospecific. Biochem. Pharmacol. 39, 787-792 (1990).
63. R. Milroy, L. Connery, S. Banham, D. Hole, A. Dorward, A. Hutcheon, B. Stack and S. B. Kaye, A randomised study of verapamil in addition to chemotherapy in small cell lung cancer. Lung Cancer 4 (Suppl.), A101 (1988). [Abstract]
64. D. A. Averill-Bates and B. Courtemanche, The effect of hyperthermia and verapamil on melphalan cytotoxicity and transport in multidrug-resistant Chinese hamster ovary cells. Radiat. Res. 143, 17-25 (1995).